National Pension Service Increases Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

National Pension Service raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 393,476 shares of the medical equipment provider’s stock after acquiring an additional 16,928 shares during the quarter. National Pension Service owned approximately 0.20% of Zimmer Biomet worth $38,757,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Brighton Jones LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at about $204,000. Sivia Capital Partners LLC bought a new position in shares of Zimmer Biomet during the second quarter valued at approximately $232,000. Janney Montgomery Scott LLC raised its holdings in shares of Zimmer Biomet by 37.0% during the second quarter. Janney Montgomery Scott LLC now owns 35,129 shares of the medical equipment provider’s stock valued at $3,204,000 after acquiring an additional 9,482 shares in the last quarter. Truist Financial Corp lifted its stake in Zimmer Biomet by 34.4% in the second quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock worth $2,446,000 after acquiring an additional 6,867 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Zimmer Biomet by 7.9% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,912 shares of the medical equipment provider’s stock valued at $2,455,000 after acquiring an additional 1,971 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ZBH shares. The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price for the company. in a research report on Friday, January 9th. Royal Bank Of Canada decreased their price target on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. Johnson Rice set a $112.00 price objective on Zimmer Biomet in a research report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $107.24.

Zimmer Biomet Stock Down 1.0%

Shares of NYSE:ZBH opened at $86.17 on Tuesday. The stock has a fifty day simple moving average of $90.86 and a two-hundred day simple moving average of $95.92. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $17.08 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 2.22 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a 12-month low of $84.59 and a 12-month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the prior year, the firm posted $1.74 EPS. Zimmer Biomet’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.